ILMN Strangle Strategy
ILMN (Illumina, Inc.), in the Healthcare sector, (Medical - Diagnostics & Research industry), listed on NASDAQ.
Illumina, Inc. provides sequencing and array-based solutions for genetic and genomic analysis. Its products and services serve customers in a range of markets enabling the adoption of genomic solutions in research and clinical settings for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. The company provides instruments and consumables used in genetic analysis; and genotyping and sequencing services, instrument service contracts, and development and licensing agreements, as well as cancer detection testing services. Its customers include genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. The company markets and distributes its products directly to customers in North America, Europe, Latin America, and the Asia-Pacific region, as well as sells through life-science distributors in various markets within Europe, the Asia-Pacific region, Latin America, the Middle East, and Africa. The company was incorporated in 1998 and is based in San Diego, California.
ILMN (Illumina, Inc.) trades in the Healthcare sector, specifically Medical - Diagnostics & Research, with a market capitalization of approximately $21.94B, a trailing P/E of 26.01, a beta of 1.42 versus the broader market, a 52-week range of 78.55-155.53, average daily share volume of 1.8M, a public-listing history dating back to 2000, approximately 9K full-time employees. These structural characteristics shape how ILMN stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.
A beta of 1.42 indicates ILMN has historically moved more than the broader market, amplifying both the directional payoff and the realized volatility relative to an index-equivalent position.
What is a strangle on ILMN?
A long strangle buys an OTM call and an OTM put at offset strikes, cheaper than a straddle but requiring a larger underlying move to profit since both wings start out-of-the-money.
Current ILMN snapshot
As of May 15, 2026, spot at $143.19, ATM IV 41.70%, IV rank 15.96%, expected move 11.96%. The strangle on ILMN below is built from the same end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 34-day expiry.
Why this strangle structure on ILMN specifically: ILMN IV at 41.70% is on the cheap side of its 1-year range, which favors premium-buying structures like a ILMN strangle, with a market-implied 1-standard-deviation move of approximately 11.96% (roughly $17.12 on the underlying). The 34-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated ILMN expiries trade a higher absolute premium for lower per-day decay. Position sizing on ILMN should anchor to the underlying notional of $143.19 per share and to the trader's directional view on ILMN stock.
ILMN strangle setup
The ILMN strangle below is built from the end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With ILMN near $143.19, the first option leg uses a $150.00 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed ILMN chain at a 34-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 ILMN shares for the stock leg in covered calls and collars).
| Action | Type | Strike / Basis | Premium (est) |
|---|---|---|---|
| Buy 1 | Call | $150.00 | $4.85 |
| Buy 1 | Put | $135.00 | $3.70 |
ILMN strangle risk and reward
- Net Premium / Debit
- -$855.00
- Max Profit (per contract)
- Unbounded
- Max Loss (per contract)
- -$855.00
- Breakeven(s)
- $126.45, $158.55
- Risk / Reward Ratio
- Unbounded
Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit.
ILMN strangle payoff curve
Modeled P&L at expiration across a range of underlying prices for the strangle on ILMN. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.
| Underlying Price | % From Spot | P&L at Expiration |
|---|---|---|
| $0.01 | -100.0% | +$12,644.00 |
| $31.67 | -77.9% | +$9,478.10 |
| $63.33 | -55.8% | +$6,312.20 |
| $94.99 | -33.7% | +$3,146.30 |
| $126.65 | -11.6% | -$19.60 |
| $158.30 | +10.6% | -$24.50 |
| $189.96 | +32.7% | +$3,141.40 |
| $221.62 | +54.8% | +$6,307.30 |
| $253.28 | +76.9% | +$9,473.20 |
| $284.94 | +99.0% | +$12,639.10 |
When traders use strangle on ILMN
Strangles on ILMN are the cheaper cousin of the straddle - traders use them when they want a large directional move but are willing to give up the inner-strike sensitivity in exchange for a lower up-front debit on the ILMN chain.
ILMN thesis for this strangle
The market-implied 1-standard-deviation range for ILMN extends from approximately $126.07 on the downside to $160.31 on the upside. A ILMN long strangle is the OTM cousin of the straddle: lower up-front cost but the underlying has to travel further past either OTM strike before the position turns profitable at expiration. Current ILMN IV rank near 15.96% sits in the lower third of its 1-year distribution, where IV often re-expands toward the mean; this favors premium-buying structures and disadvantages premium-selling structures on ILMN at 41.70%. As a Healthcare name, ILMN options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to ILMN-specific events.
ILMN strangle positions are structurally neutral / high-volatility (long premium, OTM); the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. ILMN positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move ILMN alongside the broader basket even when ILMN-specific fundamentals are unchanged. Always rebuild the position from current ILMN chain quotes before placing a trade.
Frequently asked questions
- What is a strangle on ILMN?
- A strangle on ILMN is the strangle strategy applied to ILMN (stock). The strategy is structurally neutral / high-volatility (long premium, OTM): A long strangle buys an OTM call and an OTM put at offset strikes, cheaper than a straddle but requiring a larger underlying move to profit since both wings start out-of-the-money. With ILMN stock trading near $143.19, the strikes shown on this page are snapped to the nearest listed ILMN chain strike and the premiums come straight from the end-of-day bid/ask midpoint.
- How are ILMN strangle max profit and max loss calculated?
- Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit. For the ILMN strangle priced from the end-of-day chain at a 30-day expiry (ATM IV 41.70%), the computed maximum profit is unbounded per contract and the computed maximum loss is -$855.00 per contract. Live intraday quotes will differ as the chain moves through the trading session.
- What is the breakeven for a ILMN strangle?
- The breakeven for the ILMN strangle priced on this page is roughly $126.45 and $158.55 at expiration, derived from end-of-day chain premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The current ILMN market-implied 1-standard-deviation expected move is approximately 11.96%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
- When should you consider a strangle on ILMN?
- Strangles on ILMN are the cheaper cousin of the straddle - traders use them when they want a large directional move but are willing to give up the inner-strike sensitivity in exchange for a lower up-front debit on the ILMN chain.
- How does current ILMN implied volatility affect this strangle?
- ILMN ATM IV is at 41.70% with IV rank near 15.96%, which is on the low end of its 1-year range. Premium-buying structures (long call, long put, debit spreads) are relatively cheap in this regime; premium-selling structures collect less credit per unit risk.